Preclinical data for reversible BTK inhibitor RXC005 presented at the 17th International Workshop of Chronic Lymphocytic Leukemia
15 May 2017
Redx Pharma Plc announces that preclinical efficacy data inmouse-models for its development candidate, RXC005, a reversible BTK inhibitor, has been presented in a poster session at the 17th International Workshop of Chronic Lymphocytic Leukemia (iwCLL) biennial meeting in New York City, U.S. on 14 May, 2017.
The poster, entitled “RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models”, demonstrated that RXC005 successfully inhibits wild-type BTK and C481S mutant BTK, as well as B-CellReceptor signalling in ABC-DLBCL cell lines and importantly primary CLL cells.
RXC005 was also shown to be highly selective and exhibits improved target specificity against other Tec and Src kinase family members. RXC005 demonstrated significant efficacy in ABC-DLBCL xenograft mouse models such as TMD8 and OCI-Ly10 cell lines. The poster can be found at http://redxpharma.com/pipeline/publications/
Dr Neil Murray, Chief Executive Officer of Redx Pharma, commented:
We are delighted to have presented further potent efficacy data for one of our lead development candidates, RXC005, at the prestigious iwCLL event in front of our peers and contemporaries.
Dr Richard Armer, Chief Scientific Officer of Redx Pharma, commented:
The data presented is further validation of RXC005’s potential to target both wild-type and mutant BTK, an important emerging resistance mechanism in patients with CLL progression following ibrutinib treatment. With good target engagement demonstrated in the PK/PD studies and efficacy in mouse-models, we look forward to filing an IND/CTA in late 2017 to take RXC005 into the clinic.
- XVII International Workshop of Chronic Lymphocytic Leukemia web site: http://www.iwcll2017.org
- Poster title: RXC005, a Potent and Selective, Reversible BTK Inhibitor Targeting both Wild-type and Mutant C481S BTK with Potent Efficacy in ABC-DLBCL Xenograft Mouse Models